Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles
Open accessThe DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Abstract
Therapeutics that are designed to engage RNA interference (RNAi) pathways have the potential to provide new, major ways of imparting therapy to patients. Long, double-stranded RNAs were first shown to mediate RNAi in Caenorhabditis elegans, and the potential use of RNAi for human therapy has been demonstrated by the finding that small interfering RNAs (siRNAs; approximately 21-base-pair double-stranded RNA) can elicit RNAi in mammalian cells without producing an interferon response. We are at present conducting the first in-human phase I clinical trial involving the systemic administration of siRNA to patients with solid cancers using a targeted, nanoparticle delivery system. Here we provide evidence of inducing an RNAi mechanism of action in a human from the delivered siRNA. Tumour biopsies from melanoma patients obtained after treatment show the presence of intracellularly localized nanoparticles in amounts that correlate with dose levels of the nanoparticles administered (this is, to our knowledge, a first for systemically delivered nanoparticles of any kind). Furthermore, a reduction was found in both the specific messenger RNA (M2 subunit of ribonucleotide reductase (RRM2)) and the protein (RRM2) levels when compared to pre-dosing tissue. Most notably, we detect the presence of an mRNA fragment that demonstrates that siRNA-mediated mRNA cleavage occurs specifically at the site predicted for an RNAi mechanism from a patient who received the highest dose of the nanoparticles. Together, these data demonstrate that siRNA administered systemically to a human can produce a specific gene inhibition (reduction in mRNA and protein) by an RNAi mechanism of action.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans
Fire, A., Xu, S., Montgomery, M. K., Kostas, S. A., Driver, S. E., & Mello, C. C. (1998) · Nature · doi:10.1038/35888 · Cited by 15,429 · cited 1×
“1a) containing: (1) a linear, cyclodextrin-based polymer (CDP), (2) a human transferrin protein (TF) targeting ligand displayed on the exterior of the nanoparticle to engage TF receptors (TFR) on the surface of the cancer cells, (3) a hydrophilic polymer (polyethylene glycol (PEG) used to promote nanoparticle stabilit…”
BackgroundDuplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells
Elbashir, S. M., Harborth, J., Lendeckel, W., Yalcin, A., Weber, K., & Tuschl, T. (2001) · Nature · doi:10.1038/35078107 · Cited by 9,456
Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs
Soutschek, J., Akinc, A., Bramlage, B., Charisse, K., Constien, R., Donoghue, M., Elbashir, S., Geick, A., Hadwiger, P., Harborth, J., et al. (2004) · Nature · doi:10.1038/nature03121 · Cited by 2,183
The promises and pitfalls of RNA-interference-based therapeutics
Castanotto, D., & Rossi, J. J. (2009) · Nature · doi:10.1038/nature07758 · Cited by 1,221
RNA interference targeting Fas protects mice from fulminant hepatitis
Song, E., Lee, S.-K., Wang, J., Ince, N., Ouyang, N., Min, J., Chen, J., Shankar, P., & Lieberman, J. (2003) · Nature Medicine · doi:10.1038/nm828 · Cited by 1,110
RNAi therapeutics: a potential new class of pharmaceutical drugs
Bumcrot, D., Manoharan, M., Koteliansky, V., & Sah, D. W. Y. (2006) · Nature Chemical Biology · doi:10.1038/nchembio839 · Cited by 1,085
RNA interference in adult mice
McCaffrey, A. P., Meuse, L., Pham, T.-T. T., Conklin, D. S., Hannon, G. J., & Kay, M. A. (2002) · Nature · doi:10.1038/418038a · Cited by 1,059
Davis, M. E. (2009) · Molecular Pharmaceutics · doi:10.1021/mp900015y · Cited by 977
Self-citationSequence- and target-independent angiogenesis suppression by siRNA via TLR3
Kleinman, M. E., Yamada, K., Takeda, A., Chandrasekaran, V., Nozaki, M., Baffi, J. Z., Albuquerque, R. J. C., Yamasaki, S., Itaya, M., Pan, Y., et al. (2008) · Nature · doi:10.1038/nature06765 · Cited by 929
Bartlett, D. W., Su, H., Hildebrandt, I. J., Weber, W. A., & Davis, M. E. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0707461104 · Cited by 803
Self-citation
Cited by
Items 201–255 of 255
Stirland, D. L., Nichols, J. W., Miura, S., & Bae, Y. H. (2013) · Journal of Controlled Release · doi:10.1016/j.jconrel.2013.09.026 · Cited by 225
Lipid and Polymer-Based Nanoparticle siRNA Delivery Systems for Cancer Therapy
Mainini, F., & Eccles, M. R. (2020) · Molecules · doi:10.3390/molecules25112692 · Cited by 224
Polymeric vehicles for nucleic acid delivery
Piotrowski-Daspit, A. S., Kauffman, A. C., Bracaglia, L. G., & Saltzman, W. M. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.06.014 · Cited by 224
“reported on the first polymeric NP-based gene delivery system (CALAA-01) tested in a Phase I trial for solid cancers [183].”
BackgroundSmooth Muscle Enriched Long Noncoding RNA ( SMILR ) Regulates Cell Proliferation
Ballantyne, M. D., Pinel, K., Dakin, R., Vesey, A. T., Diver, L., Mackenzie, R., Garcia, R., Welsh, P., Sattar, N., Hamilton, G., et al. (2016) · Circulation · doi:10.1161/circulationaha.115.021019 · Cited by 223
Theranostic nanoparticles for future personalized medicine
Ryu, J. H., Lee, S., Son, S., Kim, S. H., Leary, J. F., Choi, K., & Kwon, I. C. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.04.027 · Cited by 222
“This sequence specific suppression of targeted gene can be utilized for efficient therapy through the decrease of targeted molecules related with the disease [50].”
BackgroundSmall interfering RNAs (siRNAs) in cancer therapy: a nano-based approach
Mahmoodi Chalbatani, G., Dana, H., Gharagouzloo, E., Grijalvo, S., Eritja, R., Logsdon, C. D., Memari, F., Miri, S. R., Rezvani Rad, M., & Marmari, V. (2019) · International Journal of Nanomedicine · doi:10.2147/ijn.s200253 · Cited by 221
Crosstalk between TGF-β signaling and the microRNA machinery
Butz, H., Rácz, K., Hunyady, L., & Patócs, A. (2012) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2012.04.003 · Cited by 215
A review of the current status of siRNA nanomedicines in the treatment of cancer
Resnier, P., Montier, T., Mathieu, V., Benoit, J.-P., & Passirani, C. (2013) · Biomaterials · doi:10.1016/j.biomaterials.2013.04.060 · Cited by 210
“These nanoparticles were injected intravenously in three patients and proved effective against tumor tissues [164].”
Xu, L., & Anchordoquy, T. (2011) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.22243 · Cited by 209
Multifunctional Envelope-Type siRNA Delivery Nanoparticle Platform for Prostate Cancer Therapy
Xu, X., Wu, J., Liu, Y., Saw, P. E., Tao, W., Yu, M., Zope, H., Si, M., Victorious, A., Rasmussen, J., et al. (2017) · ACS Nano · doi:10.1021/acsnano.6b07195 · Cited by 207
Nanoparticle-Based Delivery of RNAi Therapeutics: Progress and Challenges
Zhou, J., Shum, K.-T., Burnett, J., & Rossi, J. (2013) · Pharmaceuticals · doi:10.3390/ph6010085 · Cited by 205
“for an RNAi gene silencing mechanism in humans by a modified 5' rapid amplification of cDNA ends (RACE) assay [37].”
MethodZheng, C., Zheng, M., Gong, P., Deng, J., Yi, H., Zhang, P., Zhang, Y., Liu, P., Ma, Y., & Cai, L. (2013) · Biomaterials · doi:10.1016/j.biomaterials.2013.01.053 · Cited by 200
“A variety of siRNA-based therapeutics have been developed, showing great promise in disease treatments [5,6].”
BackgroundGrimm, D., Wang, L., Lee, J. S., Schürmann, N., Gu, S., Börner, K., Storm, T. A., & Kay, M. A. (2010) · Journal of Clinical Investigation · doi:10.1172/jci43565 · Cited by 196
“Hence, as with shRNAs, care must likewise be taken especially with the latest proficient siRNA formulations (59, 60) to avoid in vivo Ago-2 saturation and associated adverse effects in clinical settings.”
BackgroundNgamcherdtrakul, W., Morry, J., Gu, S., Castro, D. J., Goodyear, S. M., Sangvanich, T., Reda, M. M., Lee, R., Mihelic, S. A., Beckman, B. L., et al. (2015) · Advanced Functional Materials · doi:10.1002/adfm.201404629 · Cited by 195
Computational models for lncRNA function prediction and functional similarity calculation
Chen, X., Sun, Y.-Z., Guan, N.-N., Qu, J., Huang, Z.-A., Zhu, Z.-X., & Li, J.-Q. (2019) · Briefings in Functional Genomics · doi:10.1093/bfgp/ely031 · Cited by 189
Efficient nanocarriers of siRNA therapeutics for cancer treatment
Subhan, M. A., & Torchilin, V. P. (2019) · Translational Research · doi:10.1016/j.trsl.2019.07.006 · Cited by 183
Intratumoral Immunotherapy for Early-stage Solid Tumors
Hong, W. X., Haebe, S., Lee, A. S., Westphalen, C. B., Norton, J. A., Jiang, W., & Levy, R. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-3642 · Cited by 183
Cellular Uptake and Intracellular Trafficking of Antisense and siRNA Oligonucleotides
Juliano, R. L., Ming, X., & Nakagawa, O. (2012) · Bioconjugate Chemistry · doi:10.1021/bc200377d · Cited by 181
Ross, S. J., Revenko, A. S., Hanson, L. L., Ellston, R., Staniszewska, A., Whalley, N., Pandey, S. K., Revill, M., Rooney, C., Buckett, L. K., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aal5253 · Cited by 177
“These include ligand-oligonucleotide conjugates [such as N-acetylgalactosamine conjugation for effective delivery to hepatocytes (47)], lipid- and polymer-based nanoparticles (48, 49), targeted delivery with antibody conjugates (50), and the combination with small molecules that enhance uptake and activity of oligonuc…”
BackgroundOcta-functional PLGA nanoparticles for targeted and efficient siRNA delivery to tumors
Zhou, J., Patel, T. R., Fu, M., Bertram, J. P., & Saltzman, W. M. (2012) · Biomaterials · doi:10.1016/j.biomaterials.2011.09.061 · Cited by 176
“Polyplexes of a cyclodextrin-containing polymer are the only polymer-based systems in current clinical trials, as well as the only targeted carrier [6].”
In vivo delivery of RNAi with lipid-based nanoparticles
Huang, L., & Liu, Y. (2011) · Annual Review of Biomedical Engineering · doi:10.1146/annurev-bioeng-071910-124709 · Cited by 174
Barroso, M. M. (2011) · Journal of Histochemistry & Cytochemistry · doi:10.1369/0022155411398487 · Cited by 174
“The QD labeling of Tfn does not affect its clathrin-mediated endocytosis via binding to TFR (Chithrani and Chan 2007; McGrath and Barroso 2008; Tekle et al. 2008) (Fig.”
BackgroundInfluentialSun, R., Liu, Y., Li, S.-Y., Shen, S., Du, X.-J., Xu, C.-F., Cao, Z.-T., Bao, Y., Zhu, Y.-H., Li, Y.-P., et al. (2015) · Biomaterials · doi:10.1016/j.biomaterials.2014.10.018 · Cited by 172
Leveraging Physiology for Precision Drug Delivery
Sun, W., Hu, Q., Ji, W., Wright, G., & Gu, Z. (2017) · Physiological Reviews · doi:10.1152/physrev.00015.2016 · Cited by 169
Reductively Responsive siRNA-Conjugated Hydrogel Nanoparticles for Gene Silencing
Dunn, S. S., Tian, S., Blake, S., Wang, J., Galloway, A. L., Murphy, A., Pohlhaus, P. D., Rolland, J. P., Napier, M. E., & DeSimone, J. M. (2012) · Journal of the American Chemical Society · doi:10.1021/ja300174v · Cited by 168
RNA Interference and Cancer Therapy
Wang, Z., Rao, D. D., Senzer, N., & Nemunaitis, J. (2011) · Pharmaceutical Research · doi:10.1007/s11095-011-0604-5 · Cited by 167
Van Woensel, M., Wauthoz, N., Rosière, R., Mathieu, V., Kiss, R., Lefranc, F., Steelant, B., Dilissen, E., Van Gool, S. W., Mathivet, T., et al. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.02.032 · Cited by 166
The ribonucleotide reductase large subunit (RRM1) as a predictive factor in patients with cancer
Jordheim, L. P., Sève, P., Trédan, O., & Dumontet, C. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70244-8 · Cited by 164
Lipid nanoparticles for short interfering RNA delivery
Leung, A. K. K., Tam, Y. Y. C., & Cullis, P. R. (2014) · Advances in genetics · doi:10.1016/b978-0-12-800148-6.00004-3 · Cited by 158
Thorley, A. J., Ruenraroengsak, P., Potter, T. E., & Tetley, T. D. (2014) · ACS Nano · doi:10.1021/nn505399e · Cited by 146
Treatment of NRAS-mutant melanoma
Johnson, D. B., & Puzanov, I. (2015) · Current Treatment Options in Oncology · doi:10.1007/s11864-015-0330-z · Cited by 139
PEGylated nanomedicines: recent progress and remaining concerns
Vllasaliu, D., Fowler, R., & Stolnik, S. (2014) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2014.866651 · Cited by 137
“A Phase I clinical trial outcome showed that a Tf-containing nanoparticle formulation used in delivering siRNA to cancer patients delivers functional siRNA to melanoma tumours in a dose-dependent manner [66].”
BackgroundNanotechnology: emerging tools for biology and medicine
Wong, I. Y., Bhatia, S. N., & Toner, M. (2013) · Genes & Development · doi:10.1101/gad.226837.113 · Cited by 132
Ledderose, C., Möhnle, P., Limbeck, E., Schütz, S., Weis, F., Rink, J., Briegel, J., & Kreth, S. (2012) · Critical Care Medicine · doi:10.1097/ccm.0b013e31825b8ebc · Cited by 130
Ultrasensitive tumour-penetrating nanosensors of protease activity
Kwon, E. J., Dudani, J. S., & Bhatia, S. N. (2017) · Nature Biomedical Engineering · doi:10.1038/s41551-017-0054 · Cited by 131
Godinho, B. M. D. C., Ogier, J. R., Darcy, R., O’Driscoll, C. M., & Cryan, J. F. (2013) · Molecular Pharmaceutics · doi:10.1021/mp3003946 · Cited by 126
Shi, B., Keough, E., Matter, A., Leander, K., Young, S., Carlini, E., Sachs, A. B., Tao, W., Abrams, M., Howell, B., et al. (2011) · Journal of Histochemistry & Cytochemistry · doi:10.1369/0022155411410885 · Cited by 125
“The first siRNA clinical trial that used a targeted nanoparticle delivery system was reported (Davis et al. 2010) in which a human transferrin protein targeting ligand was displayed on the exterior of a polymer nanoparticle to engage transferrin receptors of patients with melanoma after systemic…”
BackgroundInfluentialThe genetics and biology of KRAS in lung cancer
Westcott, P. M. K., & To, M. D. (2013) · Chinese Journal of Cancer · doi:10.5732/cjc.012.10098 · Cited by 116
Core-Shell type lipid/rPAA-Chol polymer hybrid nanoparticles for in vivo siRNA delivery
Gao, L.-Y., Liu, X.-Y., Chen, C.-J., Wang, J.-C., Feng, Q., Yu, M.-Z., Ma, X.-F., Pei, X.-W., Niu, Y.-J., Qiu, C., et al. (2014) · Biomaterials · doi:10.1016/j.biomaterials.2013.11.046 · Cited by 114
Development of siRNA Payloads to Target KRAS -Mutant Cancer
Yuan, T. L., Fellmann, C., Lee, C.-S., Ritchie, C. D., Thapar, V., Lee, L. C., Hsu, D. J., Grace, D., Carver, J. O., Zuber, J., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0900 · Cited by 113
“Sensor siRNAs can be effectively delivered in vivo To test the therapeutic efficacy of Sensor siRNAs in vivo, we used previously characterized cyclodextrin-polymer nanoparticles (29, 30) to deliver Sensor siRNAs to tumors in mice.”
BackgroundMethodSystemic mRNA delivery to the lungs by functional polyester-based carriers
Yan, Y., Xiong, H., Zhang, X., Cheng, Q., & Siegwart, D. J. (2017) · Biomacromolecules · doi:10.1021/acs.biomac.7b01356 · Cited by 111
Exosome-based small RNA delivery: Progress and prospects
Lu, M., Xing, H., Xun, Z., Yang, T., Ding, P., Cai, C., Wang, D., & Zhao, X. (2018) · Asian Journal of Pharmaceutical Sciences · doi:10.1016/j.ajps.2017.07.008 · Cited by 97
“[19] Davis ME, Zuckerman JE, Choi CHJ, et al.”
BackgroundDevelopment of Therapeutic-Grade Small Interfering RNAs by Chemical Engineering
Bramsen, J. B., & Kjems, J. (2012) · Frontiers in Genetics · doi:10.3389/fgene.2012.00154 · Cited by 92
“…the treatment of at least 16 diseases (http://maps.google.com/maps/ms?ie=UTF8&source=embed&oe =UTF8&msa=0&msid=117696484602143675789.000476c449bf3 97da6d6c; DeVincenzo et al., 2008; Davis et al., 2010; Leachman et al., 2010; Burnett et al., 2011; Davidson and McCray, 2011; Burnett and Rossi, 2012).”
BackgroundInfluentialCTR1 Silencing Inhibits Angiogenesis by Limiting Copper Entry into Endothelial Cells
Narayanan, G., R., B. S., Vuyyuru, H., Muthuvel, B., & Konerirajapuram Natrajan, S. (2013) · PLoS ONE · doi:10.1371/journal.pone.0071982 · Cited by 83
“Davis et al showed for the first time that systemic administration of siRNA targeting M2 subunit of ribonucleotide reductase protein in malignant melanoma can be beneficial [36].”
BackgroundExosome-mediated delivery of siRNA molecules in cancer therapy: triumphs and challenges
Ubanako, P., Mirza, S., Ruff, P., & Penny, C. (2024) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2024.1447953 · Cited by 68
Intraventricular Delivery of siRNA Nanoparticles to the Central Nervous System
Shyam, R., Ren, Y., Lee, J., Braunstein, K. E., Mao, H.-Q., & Wong, P. C. (2015) · Molecular Therapy - Nucleic Acids · doi:10.1038/mtna.2015.15 · Cited by 58
Sun, Y., Zhao, Y., Zhao, X., Lee, R. J., Teng, L., & Zhou, C. (2017) · Molecules · doi:10.3390/molecules22101724 · Cited by 56
Banerjee, S. R., Foss, C. A., Horhota, A., Pullambhatla, M., McDonnell, K., Zale, S., & Pomper, M. G. (2017) · Biomacromolecules · doi:10.1021/acs.biomac.6b01485 · Cited by 54
Non-viral therapeutic approaches to ocular diseases: An overview and future directions
Zulliger, R., Conley, S. M., & Naash, M. I. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.10.007 · Cited by 50
ScFv‐Decorated PEG‐PLA‐Based Nanoparticles for Enhanced siRNA Delivery to Her2+ Breast Cancer
Dou, S., Yang, X., Xiong, M., Sun, C., Yao, Y., Zhu, Y., & Wang, J. (2014) · Advanced Healthcare Materials · doi:10.1002/adhm.201400037 · Cited by 39
Youssef, A. E. H., Dief, A. E., El Azhary, N. M., Abdelmonsif, D. A., & El-fetiany, O. S. (2019) · Journal of Physiology and Biochemistry · doi:10.1007/s13105-018-00660-6 · Cited by 35
Nanoparticle Activation Methods in Cancer Treatment
White, B. D., Duan, C., & Townley, H. E. (2019) · Biomolecules · doi:10.3390/biom9050202 · Cited by 32
Current State of Therapeutics for HTLV-1
Wang, T. T., Hirons, A., Doerflinger, M., Morris, K. V., Ledger, S., Purcell, D. F. J., Kelleher, A. D., & Ahlenstiel, C. L. (2024) · Viruses · doi:10.3390/v16101616 · Cited by 22
Orticello, M., Fiore, M., Totta, P., Desideri, M., Barisic, M., Passeri, D., Lenzi, J., Rosa, A., Orlandi, A., Maiato, H., et al. (2015) · Oncogene · doi:10.1038/onc.2014.265 · Cited by 12
Shin, W., Lee, S.-K., Hwang, J.-H., Park, J.-C., Cho, Y.-H., Ro, E. J., Song, Y., Seo, H. R., & Choi, K.-Y. (2018) · Experimental & Molecular Medicine · doi:10.1038/s12276-018-0102-5 · Cited by 10
Metadata
- Authors
- Davis, M. E., Zuckerman, J. E., Choi, C. H. J., Seligson, D., Tolcher, A., Alabi, C. A., Yen, Y., Heidel, J. D., & Ribas, A.
- Venue
- Nature
- Published
- 2010-03-21
- Volume
- 464
- Issue
- 7291
- Pages
- 1067-1070
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2014509855
- Cited by
- 2,505
- References
- 22
- FWCI
- 94.76
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.